Journal of Clinical Pediatrics >
Clinical follow-up study of cognitive impairment in children with anti-N-methyl-D-aspartate receptor encephalitis
Received date: 2022-02-28
Online published: 2023-03-10
Objective To evaluate and follow-up the cognitive function during convalescence of anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis in children in southern China. Methods The clinical data of children with anti-NMDAR encephalitis diagnosed and treated from 2016 to 2021 were retrospectively analyzed. According to the modified Rankin Scale (mRS Score) in the acute stage, the patients were divided into the severe group (mRS>3) and the non-severe group (mRS≤3). The results of Wechsler intelligence scale at the acute stage discharged from hospital and last follow-up were collected and analyzed. Results A total of 33 children (15 boys and 18 girls) were included in the analysis. The age of first onset was 6.0 (5.0~9.0) years. The clinical features in the acute stage were mainly convulsion (n=31), psycho behavioral symptoms (n=28), and movement disorder (n=28). The time from discharge to the last follow-up was 12.0 (4.0-33.0) months. At the last follow-up, the mRS Score was 0.0 (0.0~0.0), the full-scale intelligence quotient (FSIQ) was 82.4±12.1, the verbal comprehension index (VCI) was 85.6±16.7, the working memory index (WMI) was 84.7±13.5, and the processing speed index (PSI) was 83.5±11.0. The FSIQ and subtests scores of the children were lower than the normal level. No statistically significant differences was found in FSIQ and subtests between the severe group and the non-severe group (P>0.05) at the last follow-up. Ten children received two Wechsler intelligence tests. The time of the first test was 3.0 (1.0-5.7) months after the discharge of the first onset, and the time of the second test was 21.0 (15.5-28.0) months after the discharge of the first onset. FSIQ and VCI of the second test were higher than those of the first test, and the difference was statistically significant (P<0.05). Conclusions Children with anti-NMDAR encephalitis have cognitive impairment in the convalescence period. It is recommended to conduct regular intelligence assessment and timely reasonable intervention.
Wenxiao WU , Wenlin WU , Xiaojing LI , Chi HOU , Yiru ZENG , Bingwei PENG , Haixia ZHU , Yang TIAN , Yuan ZHAO , Wenxiong CHEN . Clinical follow-up study of cognitive impairment in children with anti-N-methyl-D-aspartate receptor encephalitis[J]. Journal of Clinical Pediatrics, 2023 , 41(3) : 219 -223 . DOI: 10.12372/jcp.2023.22e0280
[1] | 中华医学会神经病学分会. 中国自身免疫性脑炎诊治专家共识[J]. 中华神经科杂志, 2017, 50(2): 91-98. |
[2] | Gibson LL, McKeever A, Coutinho E, et al. Cognitive impact of neuronal antibodies: encephalitis and beyond[J]. Transl Psychiatry, 2020, 10(1): 304. |
[3] | Li X, Hou C, Wu WL, et al. Pediatric anti-N-methyl-D-aspartate receptor encephalitis in southern China: analysis of 111 cases[J]. J Neuroimmunol, 2021, 352: 577479. |
[4] | Cainelli E, Nosadini M, Sartori S, et al. Neuropsychological and psychopathological profile of anti-NMDAR encephalitis: a possible pathophysiological model for pediatric neuropsychiatric disorders[J]. Arch Clin Neuropsychol, 2019, 34(8): 1309-1319. |
[5] | Matricardi S, Patrini M, Freri E, et al. Cognitive and neuropsychological evolution in children with anti-NMDAR encephalitis[J]. J Neurol, 2016, 263(4): 765-771. |
[6] | Aarsen FK, van Oosterhout MP, et al. Long-term neuropsychological outcome following pediatric anti-NMDAR encephalitis[J]. Neurology, 2018, 90(22): e1997-e2005. |
[7] | Graus F, Titulaer MJ, Balu R, et al. A clinical approach to diagnosis of autoimmune encephalitis[J]. Lancet Neurol, 2016, 15(4): 391-404. |
[8] | van Swieten JC, Koudstaal PJ, Visser MC, et al. Interobserver agreement for the assessment of handicap in stroke patients[J]. Stroke, 1988, 19(5): 604-607. |
[9] | Cellucci T, Van Mater H, Graus F, et al. Clinical approach to the diagnosis of autoimmune encephalitis in the pediatric patient[J]. Neurol Neuroimmunol Neuroinflamm, 2020, 7(2): e663. |
[10] | 张厚粲. 韦氏儿童智力量表第四版(WISC-IV)中文版的修订[J]. 心理科学, 2009, 32(5): 1177-1179. |
[11] | Lynch DR, Rattelle A, Dong YN, et al. Anti-NMDA receptor encephalitis: clinical features and basic mechanisms[J]. Adv Pharmacol, 2018, 82: 235-260. |
[12] | Huang Q, Xie Y, Hu Z, et al. Anti-N-methyl-D-aspartate receptor encephalitis: a review of pathogenic mechanisms, treatment, prognosis[J]. Brain Res, 2020, 1727: 146549. |
[13] | McKeon GL, Robinson GA, Ryan AE, et al. Cognitive outcomes following anti-N-methyl-D-aspartate receptor encephalitis: a systematic review[J]. J Clin Exp Neuropsychol, 2018, 40(3): 234-252. |
[14] | McKeon GL, Scott JG, Spooner DM, et al. Cognitive and social functioning deficits after anti-N-methyl-D-aspartate receptor encephalitis: an exploratory case series[J]. J Int Neuropsychol Soc, 2016, 22(8): 828-838. |
[15] | Finke C, Kopp UA, Prüss H, et al. Cognitive deficits following anti-NMDA receptor encephalitis[J]. J Neurol Neurosurg Psychiatry, 2012, 83(2): 195-198. |
[16] | Titulaer MJ, McCracken L, Gabilondo I, et al. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study[J]. Lancet Neurol, 2013, 12(2): 157-165. |
[17] | Broadley J, Seneviratne U, Beech P, et al. Prognosticating autoimmune encephalitis: a systematic review[J]. J Autoimmun, 2019, 96: 24-34. |
[18] | Howarth RA, Vova J, Blackwell LS. Early functional outcomes for pediatric patients diagnosed with anti-N-methyl-D-aspartate receptor encephalitis during inpatient rehabilitation[J]. Am J Phys Med Rehabil, 2019, 98(7): 529-535. |
[19] | 徐玄玄, 靳培娜, 马威, 等. 抗NMDAR脑炎患儿痫性发作临床特征及预后[J]. 临床儿科杂志, 2020, 38(5): 367-369. |
/
〈 |
|
〉 |